Advertisement

Author: Rebecca Shover

IO-Only or in Chemo-IO Regimens NSCLC Subgroups

Immunotherapy (IO) + chemotherapy ± anti-angiogenics comprise FDA-approved 1L regimens for metastatic non-small cell lung cancer (NSCLC), with IO-only therapy approved only for PD-L1+ NSCLC. Patients with PD-L1 scores from...

Read More

The Insider’s Guide to ASCO 2021: Ovarian Cancer

The ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application...

Read More

Challenges in Treating Tardive Dyskinesia

By: Cecilia Peterson; Amanda Glazar; Chirag Shah; Prakash Masand; Michael Lemon Introduction: Tardive Dyskinesia (TD) refers to abnormal, involuntary, choreoathetoid movements of the tongue, lips, face, trunk, and extremities...

Read More

For latest news and updates
Email-id is invalid